Effect of the pyridoindole antioxidant stobadine on development of experimental diabetic cataract and on lens protein oxidation in rats: Comparison with vitamin E and BHT

Molecular Vision

Volumn 11, Issue , 2005, Pages 56-65

  Kyselova, Zuzana ^a   Gajdosik, Andrej ^a   Gajdosikova, Alena ^a   Ulicna, Olga ^b   Mihalova, Danica ^a   Karasu, Cimen ^c   Stefek, Milan ^a  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BIOLOGICAL MARKER; BUTYLCRESOL; CARBOLINE DERIVATIVE; CARBONYL DERIVATIVE; FREE RADICAL; GLUCOSE; LENS PROTEIN; LIPID; MALONALDEHYDE; PHENOL DERIVATIVE; STOBADINE; STREPTOZOCIN; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; BODY WEIGHT; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPID OXIDATION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; BUTYLATED HYDROXYTOLUENE; CARBOLINES; CATARACT; CRYSTALLINS; DIABETES MELLITUS, EXPERIMENTAL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DRUG COMBINATIONS; LENS, CRYSTALLINE; MALE; MALONDIALDEHYDE; OXIDATION-REDUCTION; RATS; RATS, WISTAR; VITAMIN E;

EID: 20444442574     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Bron AJ, Brown NA, Harding JJ, Ganea E. The lens and cataract in diabetes. Int Ophthalmol Clin 1998; 38:37-67.
2. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85:746-53.
3. Hockwin O, Kojima M, Muller-Breitenkamp U, Wegener A. Lens and cataract research of the 20th century: a review of results, errors and misunderstandings. Dev Ophthalmol 2002; 35:1-11.
4. Bhuyan KC, Bhuyan DK. Molecular mechanism of cataractogenesis: III. Toxic metabolites of oxygen as initiators of lipid peroxidation and cataract. Curr Eye Res 1984; 3:67-81.
5. Altomare E, Vendemiale G, Grattagliano I, Angelini P, Micelli-Ferrari T, Cardia L. Human diabetic cataract: role of lipid peroxidation. Diabete Metab 1995; 21:173-9.
6. Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997; 27:141-7.
7. Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical production. Exp Eye Res 1999; 68:457-64.
8. Boscia F, Grattagliano I, Vendemiale G, Micelli-Ferrari T, Altomare E. Protein oxidation and lens opacity in humans. Invest Ophthalmol Vis Sci 2000; 41:2461-5.
9. Ross WM, Creighton MO, Stewart-DeHaan PJ, Sanwal M, Hirst M, Trevithick JR. Modelling cortical cataractogenesis: 3. In vivo effects of vitamin E on cataractogenesis in diabetic rats. Can J Ophthalmol 1982; 17:61-6.
10. Ansari NH, Srivastava SK. Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochem Biophys Res Commun 1990; 168:939-43.
11. Ohta Y, Yamasaki T, Niwa T, Majima Y, Ishiguro I. Preventive effect of topical vitamin E-containing liposome instillation on the progression of galactose cataract. Comparison between 5-week- and 12-week-old rats fed a 25% galactose diet. Exp Eye Res 1999; 68:747-55.
12. Agardh E, Hultberg B, Agardh C. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr Eye Res 2000; 21:543-9.
13. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001; 17:888-95.
14. Knekt P, Heliovaara M, Rissanen A, Aromaa A, Aaran RK. Serum antioxidant vitamins and risk of cataract. BMJ 1992; 305:1392-4.
15. Leske MC, Chylack LT Jr, He Q, Wu SY, Schoenfeld E, Friend J, Wolfe J. Antioxidant vitamins and nuclear opacities: the longitudinal study of cataract. Ophthalmology 1998; 105:831-6.
16. Jacques PF, Chylack LT Jr, Hankinson SE, Khu PM, Rogers G, Friend J, Tung W, Wolfe JK, Padhye N, Willett WC, Taylor A. Long-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol 2001; 119:1009-19.
17. Horakova L, Stolc S. Antioxidant and pharmacodynamic effects of pyridoindole stobadine. Gen Pharmacol 1998; 30:627-38.
18. Stefek M, Krizanova L, Trnkova Z. Oxidative modification of serum albumin in an experimental glycation model of diabetes mellitus in vitro: effect of the pyridoindole antioxidant stobadine. Life Sci 1999; 65:1995-7.
19. Stefek M, Sotnikova R, Okruhlicova L, Volkovova K, Kucharska J, Gajdosik A, Gajdosikova A, Mihalova D, Hozova R, Tribulova N, Gvozdjakova A. Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium. Acta Diabetol 2000; 37:111-7.
20. Karasu C, Avci A, Canbolat O, Bali M Ozansoy G, Ceylan A, Ari N, Stefek M. Comparative effects of stobadine and vitamin E treatments on oxidative stress markers in heart and kidney of streptozotocin-diabetic rats. Free Rad Biol Med 2002; 33:S188.
21. Stefek M, Gajdosik A, Tribulova N, Navarova J, Volkovova K, Weismann P, Gajdosikova A, Drimal J, Mihalova D. The pyridoindole antioxidant stobadine attenuates albuminuria, enzymuria, kidney lipid peroxidation and matrix collagen cross-linking in streptozotocin-induced diabetic rats. Methods Find Exp Clin Pharmacol 2002; 24:565-71.
22. Pekiner B, Ulusu NN, Das-Evcimen N, Sahilli M, Aktan F, Stefek M, Stolc S, Karasu C, Antioxidants in Diabetes-Induced Complications Study Group. In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+-ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. Biochim Biophys Acta 2002; 1588:71-8.
23. Demiryurek AT, Karasu C, Stefek M, Stolc S. Effect of stobadine on leukocyte free radical generation in streptozotocin-diabetic rats: comparison with vitamin E. Pharmacology 2004; 70:1-4.
24. Kallay Z, Bittererova J, Brejcha A, Faberova V, Bezek S, Trnovec T. Plasma concentration, tissue distribution and excretion of the prospective cardioprotective agent cis-(-)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido-[4,3-b]indole dihydrochloride in rats. Arzneimittelforschung 1990; 40:974-9.
25. Stefek M, Benes L, Jergelova M, Scasnar V, Turi-Nagy L, Kocis P. Biotransformation of stobadine, a gamma-carboline antiarrhythmic and cardioprotective agent, in rat liver microsomes. Xenobiotica 1987; 17:1067-73.
26. Stefek M, Benes L, Zelnik V. N-oxygenation of stobadine, a gamma-carboline antiarrhythmic and cardioprotective agent: the role of flavin-containing monooxygenase. Xenobiotica 1989; 19:143-50.
27. Ujhazy E, Dubovicka M, Balonova T, Jansak J, Zeljenkova D. Teratological assessment of stobadine after single and repeated administration in mice. J Appl Toxicol 1994; 14:357-63.
28. Gajdosikova A, Ujhazy E, Gajdosik A, Chalupa I, Blasko M, Tomaskova A, Liska J, Dubovicky M, Bauer V. Chronic toxicity and micronucleus assay of the new cardioprotective agent stobadine in rats. Arzneimittelforschung 1995; 45:531-6.
29. Linklater HA, Dzialoszynski T, McLeod HL, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis VIII: effects of butylated hydroxytoluene (BHT) in reducing protein leakage from lenses in diabetic rats. Exp Eye Res 1986; 43:305-14.
30. Srivastava SK, Ansari NH. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. Diabetes 1988; 37:1505-8.
31. Pollack A, Madar Z, Eisner Z, Nyska A, Oren P. Inhibitory effect of lycopene on cataract development in galactosemic rats. Metab Pediatr Syst Ophthalmol 1996-1997; 19-20:31-6.
32. Robertson JM, Donner AP, Trevithick JR. Vitamin E intake and risk of cataracts in humans. Ann N Y Acad Sci 1989; 570:372-82.
33. Robertson JM, Donner AP, Trevithick JR. A possible role for vitamins C and E in cataract prevention. Am J Clin Nutr 1991; 53:346S-351S.
34. Rouhiainen P, Rouhiainen H, Salonen JT. Association between low plasma vitamin E concentration and progression of early cortical lens opacities. Am J Epidemiol 1996; 144:496-500.
35. Ohta Y, Yamasaki T, Niwa T, Majima Y. Preventive effect of vitamin E-containing liposome instillation on cataract progression in 12-month-old rats fed a 25% galactose diet. J Ocul Pharmacol Ther 2000; 16:323-35.
36. Creighton MO, Ross WM, Stewart-DeHaan PJ, Sanwal M, Trevithick JR. Modelling cortical cataractogenesis VII: Effects of vitamin E treatment on galactose-induced cataracts. Exp Eye Res 1985; 40:213-22.
37. Trevithick JR, Linklater HA, Mitton KP, Dzialoszynski T, Sanford SE. Modeling cortical cataractogenesis: IX. Activity of vitamin E and esters in preventing cataracts and gamma-crystallin leakage from lenses in diabetic rats. Ann N Y Acad Sci 1989; 570:358-71.
38. Pilz J, Meineke I, Gleiter CH. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J Chromatogr B Biomed Sci Appl 2000; 742:315-25.
39. Ao S, Kikuchi C, Ono T, Notsu Y. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract. Invest Ophthalmol Vis Sci 1991; 32:3078-83.
40. Suryanarayana P, Krishnaswamy K, Reddy GB. Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis 2003; 9:223-30 .
41. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.
42. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990; 186:464-78.
43. Pollack A, Oren P, Stark AH, Eisner Z, Nyska A, Madar Z. Cataract development in sand and galactosemic rats fed a natural tomato extract. J Agric Food Chem 1999; 47:5122-6.
44. Hum TP, Augusteyn RC. The state of sulphydryl groups in proteins isolated from normal and cataractous human lenses. Curr Eye Res 1987; 6:1091-101.
45. Duhaiman AS. Glycation of human lens proteins from diabetic and (nondiabetic) senile cataract patients. Glycoconj J 1995; 12:618-21.
46. Kyselova Z, Garcia SJ, Gajdosikova A, Gajdosik A, Stefek M. Temporal relationship between lens protein oxidation and cataract development in streptozotocin-induced diabetic rats. Physiol Res 2005; 54/1, in press.
47. Truscott RJ, Augusteyn RC. The state of sulphydryl groups in normal and cataractous human lenses. Exp Eye Res 1977; 25:139-48.
48. Monnier VM, Stevens VJ, Cerami A. Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts. J Exp Med 1979; 150:1098-107.
49. Perry RE, Swamy MS, Abraham EC. Progressive changes in lens crystallin glycation and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats. Exp Eye Res 1987; 44:269-82.
50. Swamy MS, Abraham EC. Lens protein composition, glycation and high molecular weight aggregation in aging rats. Invest Ophthalmol Vis Sci 1987; 28:1693-701.
51. Takemoto LJ. Oxidation of cysteine residues from alpha-A crystallin during cataractogenesis of the human lens. Biochem Biophys Res Commun 1996; 223:216-20.
52. Takemoto LJ. Beta A3/A1 crystallin from human cataractous lens contains an intramolecular disulfide bond. Curr Eye Res 1997; 16:719-24.
53. Vendemiale G, Grattagliano I, Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999; 29:49-55.
54. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000; 33:S99-108.
55. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233:357-63.
56. Liggins J, Furth AJ. Role of protein-bound carbonyl groups in the formation of advanced glycation endproducts. Biochim Biophys Acta 1997; 1361:123-30.
57. Stefek M, Trnkova Z, Krizanova L. 2,4-dinitrophenylhydrazine carbonyl assay in metal-catalysed protein glycoxidation. Redox Rep 1999; 4:43-8.
58. Kilic F, Handelman GJ, Serbinova E, Packer L, Trevithick JR. Modelling cortical cataractogenesis 17: in vitro effect of a-lipoic acid on glucose-induced lens membrane damage, a model of diabetic cataractogenesis. Biochem Mol Biol Int 1995; 37:361-70.
59. Azuma M, Fukiage C, David LL, Shearer TR. Activation of calpain in lens: a review and proposed mechanism. Exp Eye Res 1997; 64:529-38.
60. Kilic F, Trevithick JR. Modelling cortical cataractogenesis. XXIX. Calpain proteolysis of lens fodrin in cataract. Biochem Mol Biol Int 1998; 45:963-78.
61. Bantseev VL, Herbert KL, Trevithick JR, Sivak JG. Mitochondria of rat lenses: distribution near and at the sutures. Curr Eye Res 1999; 19:506-16.
62. Wang X, Simpkins JW, Dykens JA, Cammarata PR. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci 2003; 44:2067-75.
63. Moor AN, Gottipati S, Mallet RT, Sun J, Giblin FJ, Roque R, Cammarata PR. A putative mitochondrial mechanism for antioxidative cytoprotection by 17beta-estradiol. Exp Eye Res 2004; 78:933-44.
64. Franko J, Pomfy M, Novakova B, Benes L. Stobadine protects against ischemia-reperfusion induced morphological alterations of cerebral microcirculation in dogs. Life Sci 1999; 65:1963-7.
65. Stefek M, Tribulova N, Gajdosik A, Gajdosikova A. The pyridoindole antioxidant stobadine attenuates histochemical changes in kidney of streptozotocin-induced diabetic rats. Acta Histochem 2002; 104:413-7.
66. Habib MP, Dickerson FD, Mooradian AD. Effect of diabetes, insulin, and glucose load on lipid peroxidation in the rat. Metabolism 1994; 43:1442-5.
67. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28:1708-16.
68. Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003; 31:1413-6.
69. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003; 278:42012-9.
70. Riley ML, Harding JJ. The reaction of malondialdehyde with lens proteins and the protective effect of aspirin. Biochim Biophys Acta 1993; 1158:107-12.
71. Libondi T, Ragone R, Vincenti D, Stiuso P, Auricchio G, Colonna G. In vitro cross-linking of calf lens alpha-crystallin by malondialdehyde. Int J Pept Protein Res 1994; 44:342-7.
72. Hipkiss AR, Worthington VC, Himsworth DT, Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim Biophys Acta 1998; 1380:46-54.
73. Kim J, Chehade J, Pinnas JL, Mooradian AD. Effect of select antioxidants on malondialdehyde modification of proteins. Nutrition 2000; 16:1079-81.
74. Mooradian AD, Reinacher D, Li JP, Pinnas JL. Malondialdehyde modification of proteins in vitro is enhanced in the presence of acetaldehyde. Nutrition 2001; 17:619-22.
75. Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1989; 1004:124-33.
76. Babizhayev MA. Accumulation of lipid peroxidation products in human cataracts. Acta Ophthalmol (Copenh) 1989; 67:281-7.
77. Simonelli F, Nesti A, Pensa M, Romano L, Savastano S, Rinaldi E, Auricchio G. Lipid peroxidation and human cataractogenesis in diabetes and severe myopia. Exp Eye Res 1989; 49:181-7.
78. Ulusu NN, Sahilli M, Avci A, Canbolat O, Ozansoy G, Ari N, Bali M, Stefek M, Stolc S, Gajdosik A, Karasu C. Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E. Neurochem Res 2003; 28:815-23.
79. Steenken S, Sundquist AR, Jovanovic SV, Crockett R, Sies H. Antioxidant activity of the pyridoindole stobadine. Pulse radiolytic characterization of one-electron-oxidized stobadine and quenching of singlet molecular oxygen. Chem Res Toxicol 1992; 5:355-60.
80. Kagan VE, Tsuchiya M, Serbinova E, Packer L, Sies H. Interaction of the pyridoindole stobadine with peroxyl, superoxide and chromanoxyl radicals. Biochem Pharmacol 1993; 45:393-400.
81. Rackova L, Stefek M, Majekova M. Structural aspects of antioxidant activity of substituted pyridoindoles. Redox Rep 2002; 7:207-14.
82. Clarke IS, Dzialoszynski T, Sanford SE, Chevendra V, Trevithick JR. Dietary strategies to prevent retinopathy in RCS rats. In: Lerman S, Tripathi RC, editors. Ocular toxicology: proceedings of the First Congress of the International Society of Ocular Toxicology. New York: Dekker; 1989. p.395-413.
83. Yamamoto K, Niki E. Interaction of alpha-tocopherol with iron: antioxidant and prooxidant effects of alpha-tocopherol in the oxidation of lipids in aqueous dispersions in the presence of iron. Biochim Biophys Acta 1988; 958:19-23.
84. Iwatsuki M, Tsuchiya J, Komuro E, Yamamoto Y, Niki E. Effects of solvents and media on the antioxidant activity of alpha-tocopherol. Biochim Biophys Acta 1994; 1200:19-26.